RegeneRx Biopharmaceuticals, Inc. (RGRX) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
Beta 4: the stock has moved about 300% more than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerRegeneRx Biopharmaceuticals, Inc. (RGRX) trades at $0.0011. RegeneRx Biopharmaceuticals, Inc. focuses on developing Thymosin beta 4-based therapeutics for tissue and organ repair. Sector: Healthcare.
Price as of · Last analyzed: Mar 17, 2026Analyst Coverage for RGRX: RGRX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
RegeneRx Biopharmaceuticals, Inc. (RGRX) Healthcare & Pipeline Overview
RegeneRx Biopharmaceuticals, Inc. is a biotechnology company specializing in the development of Thymosin beta 4-based therapeutics for tissue regeneration and repair. Their pipeline targets ophthalmic, cardiovascular, neurological, and dermatological conditions, positioning them within the regenerative medicine sector with strategic partnerships for global reach.
What Is the Investment Thesis for RGRX?
RegeneRx Biopharmaceuticals presents a high-risk, high-reward investment profile centered on its Thymosin beta 4 (Tβ4) technology platform. The company's value hinges on the successful clinical development and commercialization of its lead drug candidates, particularly RGN-259 for ophthalmic indications. Key catalysts include upcoming clinical trial results for RGN-259 in various eye conditions and potential regulatory approvals. The company's partnerships with Lee's Pharmaceutical Group and GtreeBNT Co., Ltd. offer avenues for international expansion and revenue generation. However, the company's small size, limited financial resources, and reliance on external funding pose significant risks. A negative P/E ratio of -0.02 and a substantial negative profit margin of -2249.8% highlight the company's current lack of profitability and dependence on future product success. The high beta of 4.73 indicates significant volatility relative to the market.
Based on FMP financials and quantitative analysis
RGRX Key Highlights
Market capitalization of $0.00B reflects the company's early stage and speculative nature.
- Gross margin of 100.0% indicates high potential profitability if products reach commercialization, though it currently reflects limited revenue.
- Negative P/E ratio of -0.02 underscores the company's current lack of earnings.
- Profit margin of -2249.8% highlights significant operating losses due to ongoing research and development expenses.
- Beta of 4.73 suggests the stock is significantly more volatile than the market average, reflecting the high-risk nature of biotechnology investments.
Who Are RGRX's Competitors?
RGRX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| ICCC ImmuCell Corporation | $9.75 | +1.56% | $88.2M | 79 5-pillar |
| RLYB Rallybio Corporation | $17.08 | +1.91% | $90.6M | 83 5-pillar |
| ALPX Alopexx, Inc. | $9.96 | 0.00% | $119M | 65 5-pillar |
| ORMP Oramed Pharmaceuticals Inc. | $4.49 | +0.22% | $184M | 76 5-pillar |
| ANTX AN2 Therapeutics, Inc. | $5.71 | +1.60% | $206M | 67 5-pillar |
| NAGE Niagen Bioscience Inc | $2.79 | +4.10% | $222M | 69 5-pillar |
| QTTB Q32 Bio Inc. | $8.23 | -0.24% | $245M | 67 5-pillar |
| CRMD CorMedix Inc. | $7.19 | -3.10% | $564M | 94 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are RGRX's Key Strengths?
Proprietary Thymosin beta 4 (Tβ4) technology platform.
- Potential for regenerative medicine applications across multiple therapeutic areas.
- Strategic partnerships for global development and commercialization.
- Focus on unmet medical needs in ophthalmic, cardiovascular, and dermatological conditions.
What Are RGRX's Weaknesses?
Limited financial resources and reliance on external funding.
- Small size and limited infrastructure.
- Dependence on the success of its lead product candidates.
- High risk associated with clinical development and regulatory approval.
What Are the Key Risks for RGRX?
Clinical trial failures and regulatory setbacks.
- Competition from established pharmaceutical companies and other biotechnology firms.
- Patent expirations and generic competition.
- Limited financial resources and reliance on external funding.
- Dependence on the success of its lead product candidates.
What Are RGRX's Competitive Advantages?
- Patented Thymosin beta 4 (Tβ4) technology platform.
- Strategic partnerships with established pharmaceutical companies for global reach.
- First-mover advantage in developing Tβ4-based therapeutics for specific indications.
What Does RGRX Do?
RegeneRx Biopharmaceuticals, Inc., founded in 1982 and based in Rockville, Maryland, is a biopharmaceutical company focused on developing therapeutic peptides, specifically Thymosin beta 4 (Tβ4), for tissue and organ protection, repair, and regeneration. Originally incorporated as Alpha 1 Biomedicals, Inc., the company changed its name in 2000 to reflect its evolving focus on regenerative medicine. RegeneRx's lead product candidate, RGN-259, is a preservative-free topical eye drop designed to regenerate corneal tissues damaged by injury, disease, or other pathologies, addressing conditions such as dry eye syndrome and neurotrophic keratitis. RGN-352 is an injectable formulation being developed to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications, aiming to reduce inflammation and promote tissue repair. RGN-137 is a topical gel intended for dermal wounds and the reduction of scar tissue formation. RegeneRx has established strategic partnerships with Lee's Pharmaceutical Group and GtreeBNT Co., Ltd. to expand the global reach of its Tβ4-based therapeutics. The company's core technology centers on the regenerative properties of Tβ4, a naturally occurring peptide involved in wound healing and tissue repair processes.
What Products and Services Does RGRX Offer?
- Develops Thymosin beta 4 (Tβ4)-based therapeutics.
- Focuses on tissue and organ protection, repair, and regeneration.
- Creates topical eye drops for corneal regeneration (RGN-259).
- Develops injectable formulations for cardiovascular and neurological diseases (RGN-352).
- Formulates topical gels for dermal wounds and scar reduction (RGN-137).
- Partners with other companies for global distribution and development.
How Does RGRX Make Money?
- Develops and patents Tβ4-based therapeutic candidates.
- Out-licenses its technology and products to partners for development and commercialization in specific territories.
- Generates revenue through upfront payments, milestone payments, and royalties on product sales from its partners.
What Industry Does RGRX Operate In?
RegeneRx operates within the biotechnology industry, which is characterized by high R&D costs, lengthy regulatory approval processes, and intense competition. The regenerative medicine market, where RegeneRx's Tβ4 technology is focused, is experiencing significant growth driven by an aging population and increasing demand for therapies that can repair and regenerate damaged tissues. Key competitors include companies developing novel therapies for ophthalmic, cardiovascular, and dermatological conditions. The industry is also subject to evolving regulatory landscapes and pricing pressures.
Who Are RGRX's Key Customers?
- Pharmaceutical companies (Lee's Pharmaceutical Group, GtreeBNT Co., Ltd.)
- Potential future customers: Patients suffering from dry eye syndrome, neurotrophic keratitis, cardiovascular diseases, neurological disorders, and dermal wounds.
- Healthcare providers who prescribe and administer RegeneRx's products.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Insider Activity
12 transactions · 0 purchases, 0 sales, 12 other transactions · 7 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Key Financial Metrics
Return on equity for RegeneRx Biopharmaceuticals, Inc. stands at 60.9%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.55 means current liabilities exceed short-term assets, a liquidity point worth watching.
Financial Health
RegeneRx Biopharmaceuticals, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile.
Company Profile
RegeneRx Biopharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Rockville, US. The company is led by CEO J. J. Finkelstein. RGRX has traded publicly since 2003.
RGRX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
RGRX Latest News
No recent news available for RGRX.
RGRX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for RGRX.
Price Targets
Wall Street price target analysis for RGRX.
RGRX MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for RGRX; grades run from A+ (80-100) to F (below 30).
Leadership: J. J. Finkelstein
CEO
J.J. Finkelstein has served as the CEO of RegeneRx Biopharmaceuticals, Inc. His background includes experience in managing and leading small biotechnology companies. His expertise lies in guiding companies through the complexities of drug development, clinical trials, and regulatory processes. He is responsible for overseeing the strategic direction of RegeneRx and fostering partnerships to advance the company's pipeline of Tβ4-based therapeutics.
Track Record: Under J.J. Finkelstein's leadership, RegeneRx has focused on advancing its lead product candidates, particularly RGN-259, through clinical trials. He has overseen the establishment of strategic partnerships with Lee's Pharmaceutical Group and GtreeBNT Co., Ltd. to expand the global reach of RegeneRx's Tβ4 technology. His tenure has been marked by efforts to secure funding and navigate the challenges of developing novel therapeutics.
RGRX OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that RegeneRx Biopharmaceuticals, Inc. may not meet the minimum financial standards or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited trading volume and liquidity compared to those listed on major exchanges like the NYSE or NASDAQ. Investing in OTC Other stocks carries significant risks due to the potential for lack of transparency and regulatory oversight. This tier is also known as the Pink Open Market.
- OTC Tier: OTC Other
- Limited liquidity and potential for price volatility.
- Lack of transparency and limited financial disclosures.
- Higher risk of fraud or manipulation compared to listed exchanges.
- Potential for delisting or suspension of trading.
- Dependence on external funding and potential for dilution.
- Verify the company's registration and legal status.
- Review available financial statements and disclosures.
- Assess the company's management team and their track record.
- Evaluate the company's business model and competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- Strategic partnerships with established pharmaceutical companies (Lee's Pharmaceutical Group, GtreeBNT Co., Ltd.).
- Patented Thymosin beta 4 (Tβ4) technology platform.
- Focus on developing therapeutics for unmet medical needs.
- Ongoing clinical trials for lead product candidates.
What Investors Ask About RegeneRx Biopharmaceuticals, Inc. (RGRX) — Healthcare
What do analysts say about RGRX stock?
As of March 17, 2026, there is no readily available analyst coverage or consensus for RGRX stock due to its OTC listing and small market capitalization.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market data may be limited or inconsistent.